Molecular biology of endometrial carcinoma;Biologia molekularna i diagnostyka raka endometrium

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 420-432

  Klemba, Aleksandra ^a   Kukwa, Wojciech ^b   Bartnik, Ewa ^a,c,d   Krawczyk, Tomasz ^b   ͆cińska, Anna ^b   Golik, Paweł ^a   Czarnecka, Anna M ^a,b  

^a UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Zak ad Patomorfologii Klinicznej Instytutu Centrum Zdrowia Matki Polki W odzi   (Poland)

^d Instytut Biochemii i Biofizyki PAN W Warszawie   (Poland)

Author keywords

Cancer biology; Endometrial adenocarcinoma; Endometrial carcinoma; Mitochondria; Molecular markers; MtDNA mutations

Indexed keywords

MITOCHONDRIAL DNA; TUMOR MARKER;

ADENOCARCINOMA; APOPTOSIS; CANCER STAGING; ELECTRON TRANSPORT; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; MASS SCREENING; METABOLISM; MUTATION; PATHOLOGY; REVIEW; RISK FACTOR;

ADENOCARCINOMA; APOPTOSIS; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MASS SCREENING; MUTATION; NEOPLASM STAGING; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149377830     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: Endometrial cancer. Lancet, 2005; 366: 491-505
2. Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F., Schreier P.H., Smith A.J., Staden R., Young I.G.: Sequence and organization of the human mitochondrial genome. Nature, 1981; 290: 457-465
3. Berneburg M., Kamenisch Y., Krutmann J., Rocken M.: 'To repair or not to repair-no longer a question': repair of mitochondrial DNA shielding against age and cancer. Exp. Dermatol., 2006; 15: 1005-1015
4. Bertram J.S.: The molecular biology of cancer. Mol. Aspects Med., 2000; 21: 167-223
5. Black D., Soslow R.A., Levine D.A., Tornos C., Chen S.C., Hummer A.J., Bogomolniy F., Olvera N., Barakat R.R., Boyd J.: Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J. Clin. Oncol., 2006; 24: 1745-1753
6. Bokhman J.V.: Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol., 1983; 15: 10-17
7. Brandon M., Baldi P., Wallace D.C.: Mitochondrial mutations in cancer. Oncogene, 2006; 25: 4647-4662
8. Bussaglia E., del Rio E., Matias-Guiu X., Prat J.: PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases. Hum. Pathol., 2000; 31: 312-317
9. Caduff R.F., Johnston C.M., Frank T.S.: Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am. J. Pathol., 1995; 146: 182-188
10. Chakravarty D., Srinivasan R., Ghosh S., Gopalan S., Rajwanshi A., Majumdar S.: Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int. J. Gynecol. Cancer, 2007; 17: 905-913
11. Coskun P.E., Ruiz-Pesini E., Wallace D.C.: Control region mtDNA variants: longevity, climatic adaptation, and a forensic conundrum. Proc. Natl. Acad. Sci. USA, 2003; 100: 2174-2176
12. Cust A.E., Armstrong B.K., Friedenreich C.M., Slimani N., Bauman A.: Physical activity and endometrial cancer risk: A review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control, 2007; 18: 243-258
13. Czarnecka A.M., Golik P., Bartnik E.: Mitochondrial DNA mutations in human neoplasia. J. Appl. Genet., 2006; 47: 67-78
14. Denny L., Hacker N.F., Gori J., Jones H.W., Ngan H.Y., Pecorelli S.: Staging classifications and clinical practice guidelines for gynaecologic cancers. http://www.figo.org/docs/staging-booklet.pdf (18-07.2008)
15. Erdem O., Taskiran C., Onan M.A., Erdem M., Guner H., Ataoglu O.: CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol. Oncol. 2006; 103: 1007-1011
16. Erkanli S., Kayaselcuk F., Kuscu E., Bagis T., Bolat F., Haberal A., Demirhan B.: Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int. J. Gynecol. Cancer, 2006; 16: 1412-1418
17. Feng Y.Z., Shiozawa T., Miyamoto T., Kashima H., Kurai M., Suzuki A., Konishi I.: BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin. Cancer Res., 2005; 11: 6133-6138
18. Fukuchi T., Sakamoto M., Tsuda H., Maruyama K., Nozawa S., Hirohashi S.: Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res., 1998; 58: 3526-3528
19. Gatenby R.A., Gillies R.J.: Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer, 2004; 4: 891-899
20. Goldman N.A., Katz E.B., Glenn A.S., Weldon R.H., Jones J.G., Lynch U., Fezzari M.J., Runowicz C.D., Goldberg G.L., Charron M.J.: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod. Pathol., 2006; 19: 1429-1436
21. Inaba F., Kawamata H., Teramoto T., Fukasawa I., Inaba N., Fujimori T.: PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol. Rep., 2005; 13: 17-24
22. Ito K., Suzuki T., Akahira J., Sakuma M., Saitou S., Okamoto S., Niikura H., Okamura K., Yaegashi N., Sasano H., Inoue S.: 14-3-3sigma in endometrial cancer-A possible prognostic marker in early-stage cancer. Clin. Cancer Res., 2005; 11: 7384-7391
23. Ito K., Watanabe K., Nasim S., Sasano H., Sato S., Yajima A., Silverberg S.G., Garrett C.T.: Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res., 1994; 54: 4667-4670
24. Kagan J., Srivastava S.: Mitochondria as a target for early detection and diagnosis of cancer. Crit. Rev. Clin. Lab. Sci., 2005; 42: 453-472
25. Kimura F., Watanabe J., Hata H., Fujisawa T., Kamata Y., Nishimura Y., Jobo T., Kuramoto H.: PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J. Cancer Res. Clin. Oncol., 2004; 130: 161-168
26. Larsen N.B., Rasmussen M., Rasmussen L.J.: Nuclear and mitochondrial DNA repair: similar pathways?. Mitochondrion, 2005; 5: 89-108
27. Lievre A., Blons H., Houllier A.M., Laccourreye O., Brasnu D., Beaune P., Laurent-Puig P.: Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. Br. J. Cancer, 2006; 94: 692-697
28. Liu V.W., Yang H.J., Wang Y., Tsang P.C., Cheung A.N., Chiu P.M., Ng T.Y., Wong L.C., Nagley P., Ngan H.Y.: High frequency of mitochondrial genome instability in human endometrial carcinomas. Br. J. Cancer., 2003; 89: 697-701
29. Livasy C.A., Reading F.C., Moore D.T., Boggess J.F., Lininger R.A.: EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol. Oncol., 2006; 100: 101-106
30. Loeb L.A., Wallace D.C., Martin G.M.: The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proc. Natl. Acad. Sci. USA, 2005; 102: 18769-18770
31. Lorenc A., Bryk J., Golik P., Kupryjanczyk J., Ostrowski J., Pronicki M., Semczuk A., Szolkowska M., Bartnik E.: Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. Mitochondrion, 2003; 3: 119-124
32. MacDonald N.D., Salvesen H.B., Ryan A., Iversen O.E., Akslen L.A., Jacobs I.J.: Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res., 2000; 60: 1750-1752
33. Mathupala S.P., Rempel A., Pedersen P.L.: Aberrant glycolytic metabolism of cancer cells: A remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J. Bioenerg. Biomembr., 1997; 29: 339-343
34. Mhawech P., Benz A., Cerato C., Greloz V., Assaly M., Desmond J.C., Koeffler H.P., Lodygin D., Hermeking H., Herrmann F., Schwaller J.: Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod. Pathol., 2005; 18: 340-348
35. Modugno F., Ness R.B., Chen C., Weiss N.S.: Inflammation and endometrial cancer: A hypothesis. Cancer Epidemiol. Biomarkers Prev., 2005; 14: 2840-2847
36. Monaghan H., MacWhinnie N., Williams A.R.: The role of matrix metalloproteinases-2,-7 and-9 and beta-catenin in high grade endometrial carcinoma. Histopathology, 2007; 50: 348-357
37. Morales L., Timmerman D., Neven P., Paridaens R.: Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients. Int. J. Gynecol. Cancer, 2006; 16(Suppl.2): 515-517
38. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., Weng L.P., Eng C.: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst., 2000; 92: 924-930
39. Nur S., Chuang L., Ramaswamy G.: Immunohistochemical characterization of cancer antigen in uterine cancers. Int. J. Gynecol. Cancer, 2006; 16: 1903-1910
40. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., Ko Y.H.: Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta, 2002; 1555: 14-20
41. Pejovic T., Ladner D., Intengan M., Zheng K., Fairchild T., Dillon D., Easley S., Marchetti D., Schwartz P., Lele S., Costa J., Odunsi K.: Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma. Eur. J. Cancer, 2004; 40: 2519-2524
42. Penta J.S., Johnson F.M., Wachsman J.T., Copeland W.C.: Mitochondrial DNA in human malignancy. Mutat. Res., 2001; 488: 119-133
43. Petros J.A., Baumann A.K., Ruiz-Pesini E., Amin M.B., Sun C.Q., Hall J., Lim S., Issa M.M., Flanders W.D., Hosseini S.H., Marshall F.F., Wallace D.C.: mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. USA, 2005; 102: 719-724
44. Planaguma J., Gonzalez M., Doll A., Monge M., Gil-Moreno A., Baro T., Garcia A., Xercavins J., Alameda F., Abal M., Reventos J.: The upregulation profiles of p21WAF1/CIP1 and RUNX1/AML1 correlate with myometrial infiltration in endometrioid endometrial carcinoma. Hum. Pathol., 2006; 37: 1050-1057
45. Prat J.: Prognostic parameters of endometrial carcinoma. Hum. Pathol., 2004; 35: 649-662
46. Quinn M.J., d'Onofrio A., Moller B., Black R., Martinez-Garcia C., Moller H., Rahu M., Robertson C., Schouten L.J., La Vecchia C., Boyle P.: Cancer mortality trends in the EU and acceding countries up to 2015. Ann. Oncol., 2003; 14: 1148-1152
47. Reid-Nicholson M., Iyengar P., Hummer A.J., Linkov I., Asher M., Soslow R.A.: Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol., 2006; 19: 1091-1100
48. Risinger J.I., Hayes A.K., Berchuck A., Barrett J.C.: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res., 1997; 57: 4736-4738
49. Saffari B., Jones L.A., el-Naggar A., Felix J.C., George J., Press M.F.: Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res., 1995; 55: 5693-5698
50. Saito S., Ito K., Nagase S., Suzuki T., Akahira J., Okamura K., Yaegashi N., Sasano H.: Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Sci., 2006; 97: 1308-1314
51. Salas A., Yao Y.G., Macaulay V., Vega A., Carracedo A., Bandelt H.J.: A critical reassessment of the role of mitochondria in tumorigenesis. PLoS. Med., 2005; 2: e296
52. Santin A.D., Bellone S., Gokden M., Palmieri M., Dunn D., Agha J., Roman J.J., Hutchins L., Pecorelli S., O'Brien T., Cannon M.J., Parham G.P.: Overexpression of HER-2/neu in uterine serous papillary cancer. Clin. Cancer Res., 2002; 8: 1271-1279
53. Sasaki H., Nishii H., Takahashi H., Tada A., Furusato M., Terashima Y., Siegal G.P., Parker S.L., Kohler M.F., Berchuck A.: Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res., 1993; 53: 1906-1910
54. Semczuk A., Lorenc A., Putowski L., Futyma K., Bryk J., Miotla P., Bartnik E.: Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. Oncol. Rep., 2006; 16: 1041-1045
55. Shih H.C., Shiozawa T., Kato K., Imai T., Miyamoto T., Uchikawa J., Nikaido T., Konishi I.: Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum. Pathol., 2003; 34: 471-478
56. Sivridis E., Buckley C.H., Fox H.: Type I and Type II estrogen and progesterone binding sites in endometrial carcinomas: their value in predicting survival. Int. J. Gynecol. Cancer, 1993; 3: 80-88
57. Slomovitz B.M., Broaddus R.R., Burke T.W., Sneige N., Soliman P.T., Wu W., Sun C.C., Munsell M.F., Gershenson D.M., Lu K.H.: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol., 2004; 22: 3126-3132
58. Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., Joste N.E., Prossnitz E.R.: GPR30: A novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol., 2007; 196: 386 e1-9
59. Sonoda K., Miyamoto S., Hirakawa T., Yagi H., Yotsumoto F., Nakashima M., Watanabe T., Nakano H.: Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol. Oncol., 2006; 103: 924-931
60. Wallace D.C.: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu. Rev. Genet., 2005; 39: 359-407
61. Wang Y., Liu V.W., Tsang P.C., Chiu P.M., Cheung A.N., Khoo U.S., Nagley P., Ngan H.Y.: Microsatellite instability in mitochondrial genome of common female cancers. Int. J. Gynecol. Cancer, 2006; 16(Suppl.1): 259-266
62. Warburg O.: On the origin of cancer cells. Science, 1956; 123: 309-314
63. Wojciechowska U., Didkowska J., Tarkowski W., Zatoński W.: Nowotwory złos̈liwe w Polsce w 2004 roku. Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warszawa 2006
64. Xu L., Hu Y., Chen B., Tang W., Han X., Yu H., Xiao C.: Mitochondrial polymorphisms as risk factors for endometrial cancer in southwest China. Int. J. Gynecol. Cancer, 2006; 16: 1661-1667
65. Yoneyama H., Hara T., Kato Y., Yamori T., Matsuura E.T., Koike K.: Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells. Mol. Cancer Res., 2005; 3: 14-20
66. Zanssen S., Schon E.A.: Mitochondrial DNA mutations in cancer. PLoS Med., 2005; 2L e401